Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Queensland Health
Deloitte
McKinsey
Express Scripts
Harvard Business School
Federal Trade Commission
Cantor Fitzgerald
Mallinckrodt
Cipla

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,998,581

« Back to Dashboard

Which drugs does patent 5,998,581 protect, and when does it expire?

Patent 5,998,581 protects ORBACTIV and is included in one NDA.

This patent has thirty-five patent family members in twenty-seven countries.
Summary for Patent: 5,998,581
Title: Reductive alkylation of glycopeptide antibiotics
Abstract:This invention is concerned with improved processes for reductive alkylation of glycopeptide antibiotics. The improvement residing in providing a source of copper which results in the initial production of a copper complex of the glycopeptide antibiotic. Reductive alkylation of this complex favors regioselective alkylation and increased yields. Copper complexes of the glycopeptide antibiotic starting materials and of the alkylated products are also part of the invention.
Inventor(s): Berglund; Richard Alan (Lafayette, IN), Lockwood; Nancy Anne (Mountlake Terrace, WA), Magadanz; Howard Eugene (Lafayette, ID), Zheng; Hua (Lafayette, ID)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/290,204
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 5,998,581

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,998,581

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,952,466 Reductive alkylation of glycopeptide antibiotics ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,998,581

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 010621 ➤ Subscribe
Austria 286910 ➤ Subscribe
Australia 5449798 ➤ Subscribe
Australia 723941 ➤ Subscribe
Brazil 9713523 ➤ Subscribe
Canada 2272240 ➤ Subscribe
China 100463917 ➤ Subscribe
China 1244802 ➤ Subscribe
Colombia 4650045 ➤ Subscribe
Czech Republic 300528 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
US Army
Cantor Fitzgerald
Farmers Insurance
QuintilesIMS
Cipla
Baxter
Johnson and Johnson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot